Xeris Biopharma Holdings, Inc. (XERS) Form 10-Q — Aug 6, 2026
Xeris Biopharma posted Q2 2026 total revenue of $92.1 million, up 28.7% year over year, powered by Recorlev, which grew 80.6% to $56.8 million on higher patient demand and favorable net pricing. The quarterly net loss widened to $31.1 million from $1.9 million a year ago, but almost entirely because of a one-time $30.8 million loss on extinguishing the 2028 Convertible Notes; operating income was positive at $5.2 million and first-half operating cash flow swung to a positive $18.1 million from negative $9.8 million.
Key figures
- Revenue
- 92100000
- Net Income
- -31101000
- Total Debt
- 252590000
- Revenue Yoy
- 28.7
- Total Assets
- 411905000
- Cash Position
- 121747000
- Shares Outstanding
- 182320306
- Accumulated deficit
- 700174000
- Anda bench trial date
- November 2028
- Gvoke revenue q2 2026
- 22549000
- Keveyis revenue q2 2026
- 11675000
- Operating income q2 2026
- 5173000
- Recorlev revenue q2 2026
- 56780000
- Orange book patent expiry
- March 2040
- Recorlev growth q2 yoy pct
- 80.6
- Operating cash flow h1 2026
- 18133000
- Customer concentration q2 2026
- Four customers accounted for 99% of gross product revenue
- Convertible notes principal at q2
- 33600000
- Hayfin effective interest rate pct
- 11.4
- Hayfin term loan principal due 2029
- 200000000
- Loss on debt extinguishment q2 2026
- 30782000
- Cash paid to retire converts july 2026
- 23000000
- Shares issued to retire converts july 2026
- 8600000
Price after filing
Close on the filing date to close N calendar days later (from $8.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.